The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Paul Sheppard begins chemotherapy after a prostate cancer diagnosis that changed everything. In this honest, sharp and deeply ...

For a small organ that doesn't do much, the prostate sure generates a lot of controversy. Prostate cancer is the second most common cancer in men (not counting skin cancer) and the second highest ...

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

New research has shown that change in PSA levels over time—known as PSA velocity—is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The study findings were published ...

Repeated measurements of prostate-specific antigen (PSA) improve the detection of prostate cancer, compared with a single measurement, according to a study published online January 15 in BJU ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

This is the second part of a three-part series on the PSA test for prostate cancer. Cancer of the prostate is one of the most common types of cancer among American men. More than 6 in 10 cases of ...

WASHINGTON (Reuters) - Most men over age 75 can safely discontinue screening for prostate cancer with the PSA blood test, although such screening may still benefit some older men, U.S. researchers ...

Physicians, scientists, and public health experts who long warned that PSA screening for prostate cancer is more harmful than helpful have finally gotten what they wanted: significantly fewer men are ...

Shomik Sengupta treats men with prostate cancer both as a private practitioner and as an employee of Eastern Health. He has been a recipient of grant funding from Cancer Australia for clinical trials ...